We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Transfused RBCs Rapidly Recover From Metabolic Storage Lesions

By LabMedica International staff writers
Posted on 20 Jul 2022

Directly after red blood cell (RBC) transfusion, a significant number of RBCs are cleared from the circulation; in some patients, up to 38% of the transfused RBCs are cleared in the first 24 hours. More...

During storage, RBCs undergo several metabolic and morphological changes, known as the “storage lesion.” The metabolic changes include decreased cellular levels of 2,3-diphosphoglycerate (2,3-DPG), adenosine triphosphate (ATP), and impaired redox metabolism. Decrease in the intracellular pH contributes significantly to the storage lesion.

Hematologists at the University of Amsterdam (Amsterdam, The Netherlands) conducted an open-label randomized controlled trial to study the effect of storage time and additive solution on the post-transfusion recovery (PTR) of RBCs. Twenty healthy male subjects were recruited who donated 500 mL and 200 mL of whole blood in citrate-phosphate-dextrose (CPD) at the national blood bank 35 and two days before the transfusion, respectively.

In this trial the effect of storage, phosphate-adenine-glucose-guanosine-gluconate-mannitol (PAGGGM) versus saline-adenine-glucose-mannitol (SAGM), on post-transfusion recovery (PTR) and metabolic restoration after transfusion was assessed. Subjects received an autologous biotinylated RBC concentrate stored for 35 days in SAGM or PAGGGM. As a reference for the PTR, a 2-day stored autologous biotinylated RBC concentrate stored in SAGM was simultaneously transfused. RBC phenotype and PTR were assessed after transfusion.

EDTA anti-coagulated blood samples were analyzed one day after sampling. The amount of bioRBCs was quantified by flow cytometry after staining with Streptavidin Alexa Fluor 647 conjugate. All flow cytometry experiments were performed with a flow cytometer: BD FACS, BD Fortessa + High Throughput Sampler (HTS), (BD Biosciences, San Jose, CA, USA). BioRBCs were isolated in two separate steps from the EDTA whole blood samples. This procedure was based on the differences in biotin density. In the first step, bioRBCs were isolated using magnetic beads, followed by the second step using flow cytometric cell sorting. Ultra-high pressure liquid chromatography–mass spectrometry analyses were performed using a Vanquish UHPLC coupled online to a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany).

The investigators reported that the PTR was significantly higher in the 2-day stored RBCs than in 35-day stored RBCs two and seven days after transfusion: 96% (range 90% to 99%) versus 72% (66% to 89%) and 96% (90% to 99%) versus 72% (66% to 89%), respectively. PTR of SAGM- and PAGGGM-stored RBCs did not differ significantly. Glucose and redox metabolism were better preserved in PAGGGM-stored RBCs. The differences measured in the blood bag remained present only until one day after transfusion. No differences in RBC phenotype were found besides an increased complement C3 deposition on 35-day RBCs stored in PAGGGM.

The authors concluded that despite a better metabolic profile of PAGGGM RBCs, PAGGGM storage did not lead to a higher PTR. Therefore, storage PAGGGM is not a superior alternative for storage in SAGM. Furthermore, the metabolic storage lesion was corrected within a day after transfusion. Finally, 35 days of storage resulted in a lower PTR compared with two days of storage. The study was published on July 6, 2022 in the journal Blood Advances.

Related Links:
University of Amsterdam 
BD Biosciences 
Thermo Fisher 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.